Three key individuals in Surgical Science Sweden AB (publ) (“Surgical Science”); CEO Gisli Hennermark, CFO Anna Ahlberg and CTO Anders Larsson, have agreed on the purchase of a total of 110,000 call options in Surgical Science. The options are issued by the two principal shareholders and board members Jan Bengtsson (Marknadspotential AB) and Roland Bengtsson (Semelin Kapitalförvaltning AB), which means that the call options do not entail any dilution for other shareholders upon exercise.
Holders have the right to acquire one (1) share in Surgical Science for each call option. The term of the options is approximately 2 years and 3 months and exercising the call options can take place between 10 December 2023 and 10 January 2024. The exercise price per share shall amount to SEK 334.60. The price of the call option has been set at SEK 23.10 and has been calculated using Black & Scholes' valuation model.
As of today, the issuers of the options own a total of 14,750,692 shares in Surgical Science, corresponding to 29.0 percent of the shares and votes.
Gothenburg, Sweden, September 23, 2021
Surgical Science Sweden AB (publ)
The press release is available in the attachment or via
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.